Claim 2 free vaccination-focused CE courses
Drug Store News has partnered with CE Impact to offer our readers free access to two on-demand CE courses focused on vaccinations. The Course are (click the names for full description) “Protect your patients’ health: How the Entire pharmacy team becomes vaccine advocates” and “Influenza update: Prepare for the 2018-19 flu season.”
The former course is focused on sharing how pharmacy technicians can support vaccine services in the community pharmacy and help protect patient health. The latter will offer a review of various influenza vaccines, pharmacist recommendations and recommendations for overcoming flu vaccine barriers.
Each course offers 1 contact hour of continuing pharmacy education.
To access the courses, please visit CEImpact.com and create an account. In the “Enter Partner Code” field, pharmacists enter code IMZ18P, and technicians enter the code IMZ18T and click apply, then confirm at the bottom of the page. The CPE activities will populate in your To Do folder.
After completing each activity, complete the exam and evaluation, then click submit to send to CPE monitor.
Bristol-Myers Squibb gets FDA green light for Empliciti
Bristol-Myers Squibb Company has received the Food and Drug Administration’s approval for Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.
“Empliciti plus pomalidomide and dexamethasone has been proven to extend the time that certain patients live without disease progression, giving health care professionals an effective new tool to tackle this relentless cancer,” Bristol-Myers Squibb senior vice president and head of medical Joseph Eid said. “Today’s approval reinforces the importance of immuno-oncology in blood cancers and expands the role of Empliciti to address the needs of relapsed or refractory multiple myeloma patients.”
Bristol-Myers Squibb and AbbVie are co-developing Empliciti, with Bristol-Myers Squibb solely responsible for commercial activities.
Coherus BioSciences gets FDA nod for Neulasta biosimilar
Coherus BioSciences has received the FDA’s clearance for Udenyca, which is a biosimilar of Amgen’s Neulasta. It is the first pegfilgrastim biosimilar approved by the FDA and the European Commission for patients with cancer receiving myelosuppressive chemotherapy, the company said.
Udenyca is a PEGylated growth colony-stimulating factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.
“The list price of Neulasta has nearly tripled since approval in 2002 and now represents a $4 billion annual cost burden in the United States. We believe that competition is essential in controlling burdensome price increases, and Udenyca will play an important role in curbing that spend when launched,” Coherus BioSciences chairman and CEO Denny Lanfear said.“Our in-depth understanding of the market will allow us to deliver significant value to patients, payors and providers in the U.S., including 340 billion hospitals, small clinics and small hospitals.”